PCSK9

Type I vs Type II discrimination

Assay & specimen

Human genetic evidence

Literature evidence(25)

• Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins.
  Circulation. Genomic and precision medicine · 2026 · PMID 41664920 · doi
• Intracoronary Imaging and Transcriptomic Characteristics Before and After Maximum Lipid-Lowering Therapy: YELLOW-III Study of Evolocumab and Maximum Statin Therapy in Chronic Coronary Disease.
  JACC. Cardiovascular imaging · 2026 · PMID 41758107 · doi
• Proteogenomic Analysis of Coronary Artery Calcification in Human Populations.
  Arteriosclerosis, thrombosis, and vascular biology · 2026 · PMID 41924874 · doi
• Bioactive lipids in plasma and atherogenic apoB-containing lipoproteins: Effects of statins and PCSK9 inhibitors and relevance to residual cardiovascular risk.
  Pharmacology & therapeutics · 2026 · PMID 42162924 · doi
• Soluble endoglin reflects endothelial dysfunction in myocardial infarction patients: a retrospective observational study.
  International journal of medical sciences · 2025 · PMID 40765559 · doi
• Plasma Protein Profile Associated With a Family History of Early-Onset Coronary Heart Disease.
  Circulation. Genomic and precision medicine · 2025 · PMID 41200820 · doi
• Integrated high-throughput miRNomics and lipidomics in mice with altered lipoprotein metabolism.
  Atherosclerosis · 2025 · PMID 41570408 · doi
• ​Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction.
  Journal of translational medicine · 2024 · PMID 38689297 · doi
• Platelets as an inter-player between hyperlipidaemia and atherosclerosis.
  Journal of internal medicine · 2024 · PMID 38704820 · doi
• Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition.
  European heart journal. Cardiovascular pharmacotherapy · 2023 · PMID 37468450 · doi
• Proteomic insights into the associations between obesity, lifestyle factors, and coronary artery disease.
  BMC medicine · 2023 · PMID 38049831 · doi
• Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
  Current opinion in lipidology · 2022 · PMID 35695614 · doi
• Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
  Clinical chemistry · 2021 · PMID 33257928 · doi
• Translating genetic association of lipid levels for biological and clinical application.
  Cardiovascular drugs and therapy · 2021 · PMID 33604704 · doi
• Mapping gene and gene pathways associated with coronary artery disease: a CARDIoGRAM exome and multi-ancestry UK biobank analysis.
  Scientific reports · 2021 · PMID 34385509 · doi
• PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.
  Thrombosis and haemostasis · 2019 · PMID 30605918 · doi
• PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography.
  Clinical biochemistry · 2019 · PMID 31493378 · doi
• PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions.
  Atherosclerosis · 2018 · PMID 29366988 · doi
• Endocytosis of lipoproteins.
  Atherosclerosis · 2018 · PMID 29980055 · doi
• [Congenital disorders of lipoprotein metabolism].
  Herz · 2017 · PMID 28555288 · doi
• PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
  Heart (British Cardiac Society) · 2017 · PMID 28596304 · doi
• Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention.
  European journal of preventive cardiology · 2017 · PMID 28618915 · doi
• History of lipidology and lipoprotein apheresis.
  Atherosclerosis. Supplements · 2017 · PMID 29096824 · doi
• Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases.
  Science (New York, N.Y.) · 2016 · PMID 27540175 · doi
• Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study.
  International journal of cardiology · 2016 · PMID 27810295 · doi

Clinical trials(20)

• Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome.
  NCT01109706 · COMPLETED · biological parameters dosage
• Impact of the PCSK9 Inhibitor Evolocumab on the Pharmacodynamic Effects of Clopidogrel in Patients With Atherosclerotic Cardiovascular Disease and High On-Treatment Platelet Reactivity
  NCT03096288 · PHASE4 · COMPLETED · Evolocumab, Placebo
• Functional Improvement of Non-infarcT relaTed Coronary Artery Stenosis by Extensive LDL-C Reduction With a PCSK9 Antibody
  NCT04141579 · NA · COMPLETED · Evolocumab 140 MG/ML [Repatha], Placebo
• The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)
  NCT04197453 · TERMINATED
• Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability in Patients With Coronary Artery Disease Assessed by Optical Coherence Tomography
  NCT04851769 · PHASE4 · COMPLETED · PCSK9 inhibitor plus statin, standard statin therapy, Coronary imaging follow-up
• Effect of PCSK9 Inhibitor on Acute Coronary Syndrome Patients With Multivessel Disease and Relatively Low LDL-C Level in Chinese Population (CHOICE Study)
  NCT05043740 · NA · UNKNOWN · Repatha or Praluent
• In-hospital Initiation of PCSK9 Inhibitor and Short-term Lipid Profile Alteration, as Well as In-hospital Mortality and Readmission Rate in Patients With Acute Myocardial Infarction
  NCT05184530 · COMPLETED · Evolocumab 140 MG/ML
• Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy
  NCT05802108 · PHASE4 · UNKNOWN · Evolocumab combined with statins, Statin
• Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
  NCT05976893 · PHASE4 · UNKNOWN · Evolocumab, Statin
• The Effect of Early Administration of PCSK9 Inhibitor, Alirocumab to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile, a Single Center Study, Registry Based, Pragmatic, Prospective Trial
  NCT06083961 · PHASE4 · NOT_YET_RECRUITING · Alirocumab
• A Prospective Registry to Assess Atherosclerosis Risk Factors and Their Relationship With Coronary Plaque Properties and Genetic Variations in Patients With Early Atherosclerosis of Unclear Origin.
  NCT06393894 · RECRUITING · Near infrared spectroscopy, Genetic testing for LDLR, APOB, PCSK9 and LDLRAP1 mutations and niR-126, -145 and -155 expression.
• Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography in Patients With Premature Coronary Artery Disease: a Randomized Controlled Trial
  NCT06520904 · PHASE4 · RECRUITING · PCSK9 inhibitor, Statin
• IMpact of PCSK9 inhibitoR initiatiOn Before Percutaneous Coronary Intervention on Coronary microVascular Dysfunction and Events for Acute Myocardial Infarction: a Multi-center, Open-label, Randomized, Controlled Trial
  NCT06683131 · PHASE4 · NOT_YET_RECRUITING · Tafolecimab
• Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients
  NCT06738758 · RECRUITING · PCSK9 inhibitor, Statin+Ezetimibe/Hybutimibe compound, Statin
• PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS): Study Protocol for a Multicenter Randomized Controlled Trial
  NCT06791031 · NA · NOT_YET_RECRUITING · PCSK9 inhibitor (PCSK9i)
• Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography
  NCT06863545 · NA · RECRUITING · PCSK9 inhibitors and background lipid-modifying therapy, Standard lipid-modifying therapy
• PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis (PISTIAS-2): A Multicenter, Open-label, Blinded-endpoint, Randomized Controlled Trial
  NCT06902740 · PHASE4 · RECRUITING · Recaticimab and Statin, Statin
• Impact of PCSK9 Monoclonal Antibody Very Early Administered in Hospital to Reduce Cardiovascular Events in Acute Myocardial Infarction (IMMEDIATE -MI)
  NCT07208006 · NA · RECRUITING · Standard Lipid-Lowering Therapy, Early Intensive Lipid-Lowering Therapy (PCSK9 Inhibitor)
• Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled Trial
  NCT07295366 · PHASE4 · COMPLETED · Elavolocumab(420 mg injections)
• PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary Prevention
  NCT07581808 · PHASE4 · RECRUITING · Inclisiran, Alirocumab

Omics datasets(1)

• PXD069776PRIDE
  Integrative Proteomics and Lipidomics Analysis of Post-Myocardial Infarction Patients Treated With PCSK9 Antibodies and Statins